摘要
目的观察重组组织型纤溶酶原激活物（rt—PA）溶栓治疗急性脑梗死的疗效及安全性。方法急性脑梗死患者20例，分为溶栓组和对照组各10例。溶栓组采用rt—PA0．9mg／kg；对照组采用低分子右旋糖酐500ml加丹参川芎嗪20ml静滴。用欧洲脑卒中临床肾经缺损评分标准（ESS）Bathel指数进行疗效评定。结果r-tPA组疗效明显高于对照组（P〈0．01）。结论rt-PA治疗急性脑梗死的临床疗效是安全、有效的。
Objective To investigate the safety , and efficacy in acute ischemic stroke patients treated with intravenous recombinant tissueplasminogen activator（rt-PA）. Methods 20 patients with acute cerebral infarction were randomly divided into r-tPA group（ 10例） and control group（ 10例）. rt- PA was administered in a dose of 0. 9mg/kg body weight. Whereas the control group received only routine treatment. The neurologic function deficits of patients in both groups were evaluated by ESS and Barthel index. Results rt-PA treatment was significantly higher than control group. Conclusion rt-PA can be performed safely and efficaciously in patients with acute cerebral infarction.
出处
《医学信息》
2012年第9期145-145,共1页
Journal of Medical Information
关键词
rt—PA
急性脑梗死
溶栓
临床疗效
rt-PA
Acute cerebral infarction
Thrombolytic therapy
effect of clinic
